

genzyme

GENERAL

legal

FAX

DATE: 10/8/02
TO: White Everett
AT: USPTO
FAX: (703) 746-5093

FROM: Isabelle A. S. Blundell, Ph.D.
E-MAIL: isabelle.blundell@genzyme.com
PHONE: 617-591-5698
FAX: 617-252-7977

DIRECT FAX: 617-768-9558

NO. OF PP (inc. cover): 4

Dear Sir:

Following the receipt of a Notice of Abandonment in 09/757,202, Applicants kindly request that the status of application be restored to pending in light of the copy of the Reply submitted in May 6, 2002 and the return receipt issued from the USPTO, both attached.

Notice of confidentiality: This transmission is intended only for the use of the addressee(s) listed above and may contain information that is confidential and privileged. If you are not the intended recipient, an agent of the recipient, or an agent responsible for delivering it to the intended recipient, you are notified that you have received this document in error and any use, disclosure, copying or communication of the contents of this transmission is prohibited. If you have received this transmission in error, please telephone us immediately and return the message to us by mail.
Thank you

05/06/02 16:16:00

SPTU->

617 252 7977 Right FAX

Page 001

TO:Auto-reply fax to 617 252 7977 COMPANY:

Auto-Reply Facsimile Transmission



UNITED STATES
PATENT AND
TRADEMARK OFFICE

TO:

Fax Sender at 617 252 7977

Fax Information

Date Received:

Total Pages:

5/6/02 4:12:46 PM [Eastern Daylight Time]

2 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 702.04 et seq.

Received
Cover
Page

=====>

05/06/02 16:16 FAX 617 252 7977		LEGAL DEPT-4th FLOOR		001	
Atty. Docket No. GC-106-COR					
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE					
FIRST NAMED INVENTOR:	SERIAL NO.:	FILING DATE:	ART. UNIT:	PAPER NO.	
Miller	09/757,202	Jan. 9, 2001	1623		
TITLE:			EXAMINER:		
Water Insoluble Derivatives of Polysaccharide Polymers			White Everett		
<p>CERTIFICATE OF FACSIMILE TRANSMISSION</p> <p>I hereby certify under 37 CFR 1.8(a) that this correspondence (2 pages) is being transmitted by facsimile to 703-472-9506, TC 1600 addressed to: Commissioner for Patents, Washington, D.C. 20231, on May 6, 2002.</p> <p><i>[Signature]</i> Special Agent in Charge</p>					
Commissioner for Patents Washington, D.C. 20231					
<p style="text-align: center;">REPLY</p> <p>Sir:</p> <p>In response to the Office Action mailed from the Patent Office on February 7, 2002, applicant submits the following remarks.</p> <p style="text-align: center;">REMARKS</p> <p>Claims 15-30 and 60-76 are pending and rejected. Favorable reconsideration of the pending claims is respectfully requested in view of the following remarks.</p> <p><u>Double Patenting Rejection</u></p> <p>Claims 15-30 and 60-76 are rejected over US patents 5,760,210 and 6,174,999 under the judicially created doctrine of obviousness-type double patenting. Applicant respectfully traverses the rejections as the Examiner has inappropriately relied on the content of the specification of the cited patents to formulate the instant rejections.</p> <p>In an obviousness-type double patenting rejection, the obviousness analysis rests on the evaluation of the difference between the invention defined in the pending claims and the</p>					
<p>MAILING LABEL: 106COR-Reply1.doc</p> <p>RECEIVED NEW 5/07 2:18 PM FAX 617 252 7977 FAX DEPT-4th FLOOR</p>					